Bristol-Myers Squibb Company (NYSE:BMY)‘s stock had its “outperform” rating reissued by analysts at William Blair in a report issued on Monday.
A number of other research analysts also recently commented on BMY. Vetr downgraded Bristol-Myers Squibb Company from a “buy” rating to a “hold” rating and set a $58.05 target price on the stock. in a research note on Monday, February 27th. Piper Jaffray Companies reaffirmed a “neutral” rating and issued a $60.00 price target on shares of Bristol-Myers Squibb Company in a report on Wednesday, March 8th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $66.00 price target (up previously from $64.00) on shares of Bristol-Myers Squibb Company in a report on Saturday, March 11th. BMO Capital Markets reiterated a “market perform” rating and issued a $45.00 price objective on shares of Bristol-Myers Squibb Company in a research note on Tuesday, April 4th. Finally, Robert W. Baird began coverage on Bristol-Myers Squibb Company in a research note on Tuesday, April 25th. They issued an “outperform” rating on the stock. One equities research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Bristol-Myers Squibb Company presently has a consensus rating of “Hold” and an average price target of $62.41.
Bristol-Myers Squibb Company (BMY) opened at 56.92 on Monday. Bristol-Myers Squibb Company has a 12-month low of $46.01 and a 12-month high of $77.12. The stock has a 50 day moving average price of $54.35 and a 200-day moving average price of $54.99. The stock has a market capitalization of $93.77 billion, a P/E ratio of 19.77 and a beta of 1.19.
Bristol-Myers Squibb Company (NYSE:BMY) last issued its earnings results on Thursday, April 27th. The biopharmaceutical company reported $0.84 EPS for the quarter, beating analysts’ consensus estimates of $0.72 by $0.12. Bristol-Myers Squibb Company had a return on equity of 31.86% and a net margin of 24.22%. The firm had revenue of $4.93 billion for the quarter, compared to the consensus estimate of $4.75 billion. During the same quarter in the previous year, the company posted $0.74 earnings per share. The business’s quarterly revenue was up 12.3% compared to the same quarter last year. Equities research analysts expect that Bristol-Myers Squibb Company will post $2.94 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, August 1st. Shareholders of record on Friday, July 7th will be paid a $0.39 dividend. This represents a $1.56 annualized dividend and a dividend yield of 2.74%. The ex-dividend date of this dividend is Wednesday, July 5th. Bristol-Myers Squibb Company’s dividend payout ratio is 54.17%.
WARNING: “Bristol-Myers Squibb Company (BMY) Rating Reiterated by William Blair” was posted by sleekmoney and is the property of of sleekmoney. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this report can be accessed at https://sleekmoney.com/bristol-myers-squibb-company-bmy-rating-reiterated-by-william-blair/1942612.html.
In other Bristol-Myers Squibb Company news, Director Lamberto Andreotti sold 34,000 shares of Bristol-Myers Squibb Company stock in a transaction dated Friday, April 7th. The stock was sold at an average price of $53.26, for a total value of $1,810,840.00. Following the sale, the director now owns 952,571 shares of the company’s stock, valued at approximately $50,733,931.46. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.23% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in the stock. American National Bank increased its stake in Bristol-Myers Squibb Company by 36.0% in the first quarter. American National Bank now owns 1,919 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 508 shares in the last quarter. Welch Investments LLC increased its stake in Bristol-Myers Squibb Company by 3.9% in the first quarter. Welch Investments LLC now owns 2,109 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 79 shares in the last quarter. Crestwood Advisors Group LLC purchased a new stake in Bristol-Myers Squibb Company during the first quarter valued at about $116,000. Blue Chip Partners Inc. increased its stake in Bristol-Myers Squibb Company by 0.8% in the first quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock valued at $116,000 after buying an additional 17 shares in the last quarter. Finally, Proficio Capital Partners LLC increased its stake in Bristol-Myers Squibb Company by 29.6% in the first quarter. Proficio Capital Partners LLC now owns 2,204 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 504 shares in the last quarter. 69.75% of the stock is currently owned by hedge funds and other institutional investors.
Bristol-Myers Squibb Company Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/bristol-myers-squibb-company-bmy-rating-reiterated-by-william-blair/1942612.html
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.